SCOTUS Weighs How IPR Stacks Up Against Other Forms Of Adjudication

November 30, 2017
The U.S. Supreme Court heard oral arguments Monday (Nov. 27) in a highly watched case set to determine whether the inter partes review process commonly used by generic drug stakeholders to clear the way for generic competition is unconstitutional given such cases are not subject to the same guardrails placed on federal courts. Much of the debate Monday centered on whether IPR should be treated differently than other processes overseen by the patent office for reexamining patents, as well as...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.